{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:08:56Z","timestamp":1790604536366,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.breast.2024.103831","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:20:24Z","timestamp":1730287224000},"page":"103831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["The \u201clows\u201d: Update on ER-low and HER2-low breast cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Nicola","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2024.103831_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100284","article-title":"The clinical and biological significance of estrogen receptor-low positive breast cancer","volume":"36","author":"Makhlouf","year":"2023","journal-title":"Mod Pathol : an official journal of the United States and Canadian Academy of Pathology"},{"key":"10.1016\/j.breast.2024.103831_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1015388","article-title":"Clinical implication of low estrogen receptor (ER-low) expression in breast cancer","volume":"13","author":"Reinert","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.breast.2024.103831_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-023-07040-9","article-title":"Oestrogen receptor low positive breast cancer: associations with prognosis","volume":"201","author":"Skjervold","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103831_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cac2.12191","article-title":"Estrogen receptor-low breast cancer: biology chaos and treatment paradox","volume":"41","author":"Yu","year":"2021","journal-title":"Cancer Commun"},{"key":"10.1016\/j.breast.2024.103831_bib6","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1245\/s10434-023-13846-0","article-title":"Clinical behavior, management, and treatment response of estrogen receptor low (1-10%) breast cancer","volume":"30","author":"Moldoveanu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2024.42.16_suppl.513","article-title":"The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer","volume":"42","author":"Choong","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib8","doi-asserted-by":"crossref","first-page":"LBA3","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3","article-title":"Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study","volume":"40","author":"Modi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib9","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2024.103831_bib10","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102538","article-title":"Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis","volume":"115","author":"Ergun","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2024.103831_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.32074\/1591-951X-942","article-title":"Think \"HER2\" different: integrative diagnostic approaches for HER2-low breast cancer","volume":"115","author":"Marchi\u00f2","year":"2023","journal-title":"Pathologica"},{"key":"10.1016\/j.breast.2024.103831_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.2022.40.16_suppl.1087","article-title":"Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics","volume":"40","author":"Viale","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.20517\/cdr.2022.29","article-title":"Improving HER2 testing reproducibility in HER2-low breast cancer","volume":"5","author":"Sajjadi","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.breast.2024.103831_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/his.15273","article-title":"Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study","author":"Hempenius","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2024.103831_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib17","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.breast.2024.103831_bib18","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1245\/s10434-023-14835-z","article-title":"Defining the biology of estrogen receptor-low-positive breast cancer","volume":"31","author":"Higgins","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/CEJ.0000000000000804","article-title":"Computational pathology to improve biomarker testing in breast cancer: how close are we?","author":"Sajjadi","year":"2023","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.breast.2024.103831_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5858\/arpa.2022-0370-OA","article-title":"FOXC1 and SOX10 in estrogen receptor\u2013low positive\/HER2-negative breast cancer: potential biomarkers for the basal-like phenotype prediction","volume":"148","author":"Li","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2024.103831_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.breast.2022.03.002","article-title":"Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer","volume":"63","author":"Luo","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103831_bib22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4143\/crt.2021.890","article-title":"Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer","volume":"54","author":"Yoon","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103831_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10549-021-06309-1","article-title":"Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea","volume":"189","author":"Park","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103831_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2021.02.020","article-title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - an analysis of 2765 patients from neoadjuvant clinical trials","volume":"148","author":"Villegas","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2024.103831_bib25","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.annonc.2021.08.1988","article-title":"Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort","volume":"32","author":"Schrodi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-021-06148-0","article-title":"Characterization of estrogen receptor-low-positive breast cancer","volume":"188","author":"Fei","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103831_bib27","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41416-020-1009-1","article-title":"The significance of highlighting the oestrogen receptor low category in breast cancer","volume":"123","author":"Poon","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2024.103831_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41523-023-00543-0","article-title":"Immune landscape of breast tumors with low and intermediate estrogen receptor expression","volume":"9","author":"Voorwerk","year":"2023","journal-title":"NPJ breast cancer"},{"key":"10.1016\/j.breast.2024.103831_bib29","article-title":"Assessment of estrogen receptor low positive status in breast cancer: implications for pathologists and oncologists","author":"Fusco","year":"2021","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.breast.2024.103831_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djae178","article-title":"Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer","author":"Massa","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2024.103831_bib31","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.3390\/curroncol30110706","article-title":"Estrogen-receptor-low-positive breast cancer: pathological and clinical perspectives","volume":"30","author":"Malainou","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2022.09.008","article-title":"Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: a prospective cohort study","volume":"66","author":"Xie","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2024.103831_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102761","article-title":"The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer","volume":"128","author":"Boscolo Bielo","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2024.103831_bib34","first-page":"1","article-title":"Personalizing adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer","volume":"42","author":"Pistilli","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2024.103831_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10238-024-01458-1","article-title":"Real-world experience with CDK4\/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population","volume":"24","author":"Chen","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.breast.2024.103831_bib36","first-page":"3657","article-title":"Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact","volume":"34","author":"Dieci","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.breast.2024.103831_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy","volume":"7","author":"Dieci","year":"2021","journal-title":"NPJ breast cancer"},{"key":"10.1016\/j.breast.2024.103831_bib38","article-title":"Into the twilight zone - should ER-low breast cancer be treated as triple negative breast cancer?","volume":"40","author":"Jernstr\u00f6m","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.breast.2024.103831_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13071176","article-title":"Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods","volume":"13","author":"Porta","year":"2023","journal-title":"J Personalized Med"},{"key":"10.1016\/j.breast.2024.103831_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221090351","article-title":"Estrogen receptor bio-activities determine clinical endocrine treatment options in estrogen receptor-positive breast cancer","volume":"21","author":"Xia","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.breast.2024.103831_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104148","article-title":"The CDK4\/6 inhibitors biomarker landscape: the most relevant biomarkers of response or resistance for further research and potential clinical utility","volume":"192","author":"Antonarelli","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.breast.2024.103831_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41379-020-00697-3","article-title":"Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls","volume":"34","author":"Cimino-Mathews","year":"2021","journal-title":"Mod Pathol : an official journal of the United States and Canadian Academy of Pathology, Inc"},{"key":"10.1016\/j.breast.2024.103831_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/CMAR.S202965","article-title":"Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast cancer: an evidence-based review on current options","volume":"12","author":"Grizzi","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.breast.2024.103831_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/his.14767","article-title":"Marker assessments in ER-positive breast cancers: old markers, new applications?","volume":"82","author":"Li","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2024.103831_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing","volume":"121","author":"Venetis","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2024.103831_bib46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/pgs-2023-0238","article-title":"PIK3CA testing in hormone receptor-positive\/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories","volume":"25","author":"Pepe","year":"2024","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.breast.2024.103831_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152842","article-title":"The HER2-low revolution in breast oncology: steps forward and emerging challenges","volume":"15","author":"Nicol\u00f2","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/CCO.0b013e32833f4882","article-title":"Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies","volume":"22","author":"Viale","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib49","first-page":"1","article-title":"The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer","author":"Schlam","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.breast.2024.103831_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2022.08.022","article-title":"Selecting patients with HER2-low breast cancer: getting out of the tangle","volume":"175","author":"Baez-Navarro","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2024.103831_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/tbcr-23-15","article-title":"HER2-low breast cancer: insights on pathological testing","volume":"4","author":"Liu","year":"2023","journal-title":"Transl Breast Cancer Res"},{"key":"10.1016\/j.breast.2024.103831_bib52","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2024-0052-OA","article-title":"Global study on the accuracy of human epidermal growth factor receptor 2-low diagnosis in breast cancer","author":"R\u00fcschoff","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2024.103831_bib53","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib54","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00428-022-03378-5","article-title":"Comparison of HercepTest\u2122 mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2\/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status","volume":"481","author":"R\u00fcschoff","year":"2022","journal-title":"Virchows Arch"},{"key":"10.1016\/j.breast.2024.103831_bib55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2024.103831_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.breast.2024.103831_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2024.152288","article-title":"Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry","volume":"70","author":"Wang","year":"2024","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.breast.2024.103831_bib58","article-title":"HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","volume":"134","author":"Li","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.breast.2024.103831_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12672-024-01192-w","article-title":"Antibody-drug conjugates for breast cancer: a bibliometric study and clinical trial analysis","volume":"15","author":"Xing","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14050467","article-title":"Navigating HER2-low testing in invasive breast cancer: update recommendations for pathologists","volume":"14","author":"Bornstein-Quevedo","year":"2024","journal-title":"J Personalized Med"},{"key":"10.1016\/j.breast.2024.103831_bib61","article-title":"Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: an updated systematic review and meta-analysis of clinical trials","author":"Qureshi","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.34133\/bmef.0048","article-title":"Automated HER2 scoring in breast cancer images using deep learning and pyramid sampling","volume":"5","author":"Selcuk","year":"2024","journal-title":"BME Front"},{"key":"10.1016\/j.breast.2024.103831_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/his.15273","article-title":"Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study","author":"Hempenius","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2024.103831_bib64","article-title":"Standardized pathology report for HER2 testing in compliance with 2023 ASCO\/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer","author":"Ivanova","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.breast.2024.103831_bib65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/CEJ.0000000000000781","article-title":"HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era","volume":"32","author":"Giugliano","year":"2023","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.breast.2024.103831_bib66","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-024-01079-4","article-title":"Trastuzumab-deruxtecan: redefining HER2 as a tumor agnostic biomarker","author":"Zouein","year":"2024","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231183679","article-title":"Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment","volume":"15","author":"Nader-Marta","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2024.103831_bib68","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2024.103831_bib69","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","article-title":"HER2-Low breast cancer: a new subtype?","volume":"24","author":"Corti","year":"2023","journal-title":"Curr Treat Options Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977624001620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T23:59:21Z","timestamp":1733183961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977624001620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":69,"alternative-id":["S0960977624001620"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2024.103831","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u201clows\u201d: Update on ER-low and HER2-low breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2024.103831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103831"}}